A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis | Zendy

Ludwig Kappos | Zendy; ErnstWilhelm Radue | Zendy; Paul O’Connor | Zendy; Chris H. Polman | Zendy; Reinhard Hohlfeld | Zendy; Peter A. Calabresi | Zendy; Krzysztof Selmaj | Zendy; Catherine Agoropoulou | Zendy; Małgorzata Leyk | Zendy; Lixin Zhang-Auberson | Zendy; P Burtin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

Author(s) -

Ludwig Kappos,

ErnstWilhelm Radue,

Paul O’Connor,

Chris H. Polman,

Reinhard Hohlfeld,

Peter A. Calabresi,

Krzysztof Selmaj,

Catherine Agoropoulou,

Małgorzata Leyk,

Lixin Zhang-Auberson,

P Burtin

Publication year - 2010

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0909494

Subject(s) - fingolimod , medicine , multiple sclerosis , placebo , magnetic resonance imaging , interferon beta 1a , oral administration , pharmacology , oncology , immunology , pathology , radiology , interferon beta , alternative medicine

Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end points measured on magnetic resonance imaging (MRI), as compared with either placebo or intramuscular interferon beta-1a, in phase 2 and 3 studies of multiple sclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research